
Per Munck af Rosenschold

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5262128/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	AAPM Task Group 264: The safe clinical implementation of MLC tracking in radiotherapy. Medical Physics, 2021, 48, e44-e64.	1.6	49
2	Establishment and Initial Experience of Clinical FLASH Radiotherapy in Canine Cancer Patients. Frontiers in Oncology, 2021, 11, 658004.	1.3	45
3	Volumetric modulated arc therapy dose prediction and deliverable treatment plan generation for prostate cancer patients using a densely connected deep learning model. Physics and Imaging in Radiation Oncology, 2021, 19, 112-119.	1.2	10
4	Premature Termination of a Randomized Controlled Trial on Imageâ€Guided Stereotactic Body Radiotherapy of Metastatic Spinal Cord Compression. Oncologist, 2020, 25, 210.	1.9	2
5	Multimodal soft tissue markers for bridging high-resolution diagnostic imaging with therapeutic intervention. Science Advances, 2020, 6, eabb5353.	4.7	8
6	Residual positioning errors and uncertainties for pediatric craniospinal irradiation and the impact of image guidance. Radiation Oncology, 2020, 15, 149.	1.2	2
7	Daily Adaptive Proton Therapy: Is it Appropriate to Use Analytical Dose Calculations for Plan Adaption?. International Journal of Radiation Oncology Biology Physics, 2020, 107, 747-755.	0.4	16
8	ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiotherapy and Oncology, 2019, 141, 5-13.	0.3	62
9	PO-0990 Positioning uncertainties for pediatric craniospinal irradiation and the impact of image guidance. Radiotherapy and Oncology, 2019, 133, S544-S545.	0.3	0
10	Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors. Journal of Nuclear Medicine, 2019, 60, 1053-1058.	2.8	29
11	Diabetes increases the risk of serious adverse events after re-irradiation of the spine. Radiotherapy and Oncology, 2019, 136, 130-135.	0.3	5
12	Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors. Clinical and Translational Radiation Oncology, 2019, 15, 93-98.	0.9	2
13	The dosimetric effect of residual breath-hold motion in pencil beam scanned proton therapy – An experimental study. Radiotherapy and Oncology, 2019, 134, 135-142.	0.3	7
14	A modality-adaptive method for segmenting brain tumors and organs-at-risk in radiation therapy planning. Medical Image Analysis, 2019, 54, 220-237.	7.0	31
15	Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients. Radiotherapy and Oncology, 2019, 130, 149-155.	0.3	9
16	Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 603-613.	3.3	44
17	Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control. Radiation Oncology, 2018, 13, 64.	1.2	9
18	¹⁸ Fâ€ <scp>FDG PET</scp> / <scp>CT</scp> for planning external beam radiotherapy alters therapy in 11% of 581 patients. Clinical Physiology and Functional Imaging, 2018, 38, 278-284.	0.5	6

#	Article	IF	CITATIONS
19	Retrospective estimation of heart and lung doses in pediatric patients treated with spinal irradiation. Radiotherapy and Oncology, 2018, 128, 209-213.	0.3	3
20	PO-0946: Breath-hold motion effect in pencil beam scanned proton therapy for lung cancer – experimental study. Radiotherapy and Oncology, 2018, 127, S515-S516.	0.3	0
21	EP-1812: Proton pencil beam scanning with motion emulated as spot shifts: dose reconstruction for lung cancer. Radiotherapy and Oncology, 2018, 127, S974-S975.	0.3	Ο
22	EP-2114: Prediction of recurrence patterns using diffusion driven growth modelling for glioblastoma. Radiotherapy and Oncology, 2018, 127, S1162-S1163.	0.3	0
23	Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer. Clinical and Translational Radiation Oncology, 2018, 13, 24-28.	0.9	13
24	Patterns of failure for patients with glioblastoma following O-(2-[18 F]fluoroethyl)- L -tyrosine PET- and MRI-guided radiotherapy. Radiotherapy and Oncology, 2017, 122, 380-386.	0.3	30
25	Visual outcome, endocrine function and tumor control after fractionated stereotactic radiation therapy of craniopharyngiomas in adults: findings in a prospective cohort. Acta Oncológica, 2017, 56, 415-421.	0.8	22
26	Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer. Radiotherapy and Oncology, 2017, 122, 393-399.	0.3	22
27	Target position uncertainty during visually guided deep-inspiration breath-hold radiotherapy in locally advanced lung cancer. Radiotherapy and Oncology, 2017, 123, 78-84.	0.3	33
28	Simulating intrafraction prostate motion with a random walk model. Advances in Radiation Oncology, 2017, 2, 429-436.	0.6	9
29	Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial. Radiotherapy and Oncology, 2017, 125, 223-227.	0.3	21
30	Feasibility of Pencil Beam Scanned Intensity Modulated Proton Therapy in Breath-hold for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1121-1128.	0.4	30
31	OC-0301: Target position uncertainty during visually guided breathhold radiotherapy in locally advanced NSCLC. Radiotherapy and Oncology, 2017, 123, S155-S156.	0.3	0
32	EP-1462: The impact on VMAT optimization using Type C vs B algorithms for patients with temporary gas pockets. Radiotherapy and Oncology, 2017, 123, S780-S781.	0.3	0
33	PO-0642: Influence of Introduction of VMAT and FET-PET on Treatment Outcomes for Glioblastoma Patients. Radiotherapy and Oncology, 2017, 123, S336.	0.3	0
34	Impact of beam angle choice on pencil beam scanning breath-hold proton therapy for lung lesions. Acta Oncológica, 2017, 56, 853-859.	0.8	16
35	The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 373-381.	3.3	54
36	RTHP-28. PREDICTION OF RECURRENCE PATTERNS USING DIFFUSION DRIVEN GROWTH MODELING FOR GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi224-vi224.	0.6	0

#	Article	IF	CITATIONS
37	RA-07FEASIBILITY OF EARLY POSTOPERATIVE18F-FET PET/MRI AFTER SURGERY FOR BRAIN TUMOR IN PEDIATRIC PATIENTS. Neuro-Oncology, 2016, 18, iii166.2-iii166.	0.6	0
38	A Retrospective Evaluation of the Benefit of Referring Pediatric Cancer Patients to an External Proton Therapy Center. Pediatric Blood and Cancer, 2016, 63, 262-269.	0.8	19
39	Robustness of the Voluntary Breath-Hold Approach for the Treatment of Peripheral Lung Tumors Using Hypofractionated Pencil Beam Scanning Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 95, 534-541.	0.4	35
40	Brain Tumor Segmentation Using a Generative Model with an RBM Prior on Tumor Shape. Lecture Notes in Computer Science, 2016, , 168-180.	1.0	25
41	A dosimetric comparison of real-time adaptive and non-adaptive radiotherapy: A multi-institutional study encompassing robotic, gimbaled, multileaf collimator and couch tracking. Radiotherapy and Oncology, 2016, 119, 159-165.	0.3	82
42	A generative model for segmentation of tumor and organs-at-risk for radiation therapy planning of glioblastoma patients. Proceedings of SPIE, 2016, , .	0.8	2
43	Injectable silver nanosensors: in vivo dosimetry for external beam radiotherapy using positron emission tomography. Nanoscale, 2016, 8, 11002-11011.	2.8	6
44	Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer. Radiotherapy and Oncology, 2016, 121, 64-69.	0.3	29
45	Prognostic value of 18F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial. Radiotherapy and Oncology, 2016, 121, 132-137.	0.3	31
46	Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer. Radiation Oncology, 2016, 11, 117.	1.2	3
47	SU-F-T-123: The Simulated Effect of the Breath-Hold Reproducibility Treating Locally-Advanced Lung Cancer with Pencil Beam Scanned Proton Therapy. Medical Physics, 2016, 43, 3490-3490.	1.6	0
48	Fast intra-fractional image-guidance with 6D positioning correction reduces delivery uncertainty for stereotactic radiosurgery and radiotherapy. Journal of Radiosurgery and SBRT, 2016, 4, 15-20.	0.2	9
49	Stereotactic radiosurgery versus decompressive surgery followed by postoperative radiotherapy for metastatic spinal cord compression (STEREOCORD): Study protocol of a randomized non-inferiority trial. Journal of Radiosurgery and SBRT, 2016, 4, S1-S9.	0.2	5
50	NIMC-34THE PROGNOSTIC VALUE OF POSTOPERATIVE O-(2-18F-FLUOROETHYL)-L-TYROSINE POSITRON EMISSION TOMOGRAPHY IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v161.2-v161.	0.6	2
51	Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes. ACS Nano, 2015, 9, 6985-6995.	7.3	220
52	PET/CT-guided treatment planning for paediatric cancer patients: a simulation study of proton and conventional photon therapy. British Journal of Radiology, 2015, 88, 20140586.	1.0	0
53	Use of PET/CT instead of CT-only when planning for radiation therapy does not notably increase life years lost in children being treated for cancer. Pediatric Radiology, 2015, 45, 570-581.	1.1	4
54	Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer. Scandinavian Journal of Urology, 2015, 49, 58-69.	0.6	6

#	Article	IF	CITATIONS
55	Injectable Colloidal Gold for Use in Intrafractional 2D Imageâ€Guided Radiation Therapy. Advanced Healthcare Materials, 2015, 4, 856-863.	3.9	29
56	Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. Neuro-Oncology, 2015, 17, 757-763.	0.6	58
57	PO-0780: Benefit of intra-fraction image-guidance for stereotactic radiotherapy and radiosurgery. Radiotherapy and Oncology, 2015, 115, S389.	0.3	1
58	PO-0964: Artefact quantification of liquid and solid fiducial marker in single and dual energy CT with MAR. Radiotherapy and Oncology, 2015, 115, S510.	0.3	1
59	EP-1301: Health related quality of life measurements following re-irradiation of metastatic spinal cord compression. Radiotherapy and Oncology, 2015, 115, S701-S702.	0.3	1
60	Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy. Medical Physics, 2015, 42, 2818-2826.	1.6	28
61	A treatment planning and delivery comparison of volumetric modulated arc therapy with or without flattening filter for gliomas, brain metastases, prostate, head/neck and early stage lung cancer. Acta Oncológica, 2014, 53, 1005-1011.	0.8	35
62	Automatic FDG-PET-based tumor and metastatic lymph node segmentation in cervical cancer. Proceedings of SPIE, 2014, , .	0.8	3
63	Motion management during IMAT treatment of mobile lung tumors—A comparison of MLC tracking and gated delivery. Medical Physics, 2014, 41, 101707.	1.6	18
64	Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study. Radiation Oncology, 2014, 9, 228.	1.2	18
65	Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: Minimizing the life years lost attributable to failure to control the disease and late complication risk. Acta OncolA³gica, 2014, 53, 462-470.	0.8	18
66	Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique. Neuro-Oncology, 2014, 16, 594-602.	0.6	36
67	Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiation Oncology, 2014, 9, 44.	1.2	93
68	Visual outcome after fractionated stereotactic radiation therapy of benign anterior skull base tumors. Journal of Neuro-Oncology, 2014, 118, 101-108.	1.4	26
69	Modeling positioning uncertainties of prostate cancer external beam radiation therapy using pre-treatment data. Radiotherapy and Oncology, 2014, 110, 251-255.	0.3	10
70	Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy. Radiotherapy and Oncology, 2014, 110, 441-447.	0.3	18
71	Prospective Assessment of Urinary, Gastrointestinal, and Sexual Symptoms Before, During, and After Image-Guided Intensity Modulated Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S405-S406.	0.4	0
72	The Impact of Different PTV Margins in VMAT and IMPT for Adolescents With Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, S732.	0.4	1

#	Article	IF	CITATIONS
73	Impact of Dose to the Bladder Trigone on Long-Term Urinary Function After High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 339-344.	0.4	122
74	Dosimetry for gadolinium neutron capture therapy (GdNCT). Radiation Measurements, 2013, 59, 233-240.	0.7	21
75	Doses to Carotid Arteries After Modern Radiation Therapy for Hodgkin Lymphoma: Is Stroke Still a Late Effect of Treatment?. International Journal of Radiation Oncology Biology Physics, 2013, 87, 297-303.	0.4	27
76	Three-dimensional MRI-linac intra-fraction guidance using multiple orthogonal cine-MRI planes. Physics in Medicine and Biology, 2013, 58, 4943-4950.	1.6	81
77	Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study. Radiation Oncology, 2013, 8, 262.	1.2	16
78	Modeling Freedom From Progression for Standard-Risk Medulloblastoma: A Mathematical Tumor Control Model With Multiple Modes of Failure. International Journal of Radiation Oncology Biology Physics, 2013, 87, 422-429.	0.4	5
79	Patterns and Predictors of Amelioration of Genitourinary Toxicity After High-dose Intensity-modulated Radiation Therapy for Localized Prostate Cancer: Implications for Defining Postradiotherapy Urinary Toxicity. European Urology, 2013, 64, 931-938.	0.9	38
80	Percutaneously implanted markers in peripheral lung tumours: Report of complications. Acta Oncológica, 2013, 52, 1225-1228.	0.8	9
81	Patient QA systems for rotational radiation therapy: A comparative experimental study with intentional errors. Medical Physics, 2013, 40, 031716.	1.6	98
82	The impact of leaf width and plan complexity on DMLC tracking of prostate intensity modulated arc therapy. Medical Physics, 2013, 40, 111717.	1.6	9
83	The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma. Acta Oncológica, 2013, 52, 1559-1565.	0.8	27
84	Dosimetric benefit of DMLC tracking for conventional and sub-volume boosted prostate intensity-modulated arc radiotherapy. Physics in Medicine and Biology, 2013, 58, 2349-2361.	1.6	11
85	Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Annals of Oncology, 2013, 24, 2113-2118.	0.6	121
86	PD-0416: Robust feature auto-segmentation of head and neck cancer. Radiotherapy and Oncology, 2013, 106, S160.	0.3	0
87	Stability of percutaneously implanted markers for lung stereotactic radiotherapy. Journal of Applied Clinical Medical Physics, 2013, 14, 187-195.	0.8	20
88	Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma. Neuro-Oncology, 2012, 14, 882-889.	0.6	69
89	Interobserver delineation variation in lung tumour stereotactic body radiotherapy. British Journal of Radiology, 2012, 85, e654-e660.	1.0	33
90	Risk of Developing Cardiovascular Disease After InvolvedÂNode Radiotherapy Versus Mantle Field for Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1232-1237.	0.4	91

#	Article	IF	CITATIONS
91	A Dosimetric Comparison of MLC Tracking and Gated Delivery of Arc Therapy to a Moving Target. International Journal of Radiation Oncology Biology Physics, 2012, 84, S733.	0.4	0
92	The Clinical Commissioning of Beams for Neutron Capture Therapy. , 2012, , 259-275.		0
93	Results of PET/CT Planned IMRT and Concomitant Boost to Lymph Node Metastasis in Patients With Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, S440.	0.4	0
94	The dosimetric impact of inversely optimized arc radiotherapy plan modulation for real-time dynamic MLC tracking delivery. Medical Physics, 2012, 39, 1588-1594.	1.6	18
95	Life years lost—comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer, 2012, 118, 5432-5440.	2.0	61
96	Photon and proton therapy planning comparison for malignant glioma based on CT, FDG-PET, DTI-MRI and fiber tracking. Acta Oncológica, 2011, 50, 777-783.	0.8	38
97	Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncológica, 2011, 50, 806-816.	0.8	132
98	Estimating Life Years Lost to Quantify the Potential Benefit for Pediatric Patients of Advanced Photon or Proton Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, S665.	0.4	0
99	Interaction between the biological effects of high- and low-LET radiation dose components in a mixed field exposure. International Journal of Radiation Biology, 2011, 87, 1162-1172.	1.0	17
100	Contour Propagation With Riemannian Elasticity Regularization. International Journal of Radiation Oncology Biology Physics, 2011, 81, S807.	0.4	0
101	Comparison of Cardiac Doses after Involved Node Radiotherapy and Mantle Field Treatment for Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, S19.	0.4	0
102	Artifacts in Conventional Computed Tomography (CT) and Free Breathing Four-Dimensional CT Induce Uncertainty in Gross Tumor Volume Determination. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1573-1580.	0.4	53
103	"Abscopal―Effect of Radiation Therapy Combined with Immune-Therapy Using IFN-γ Gene Transfected Syngeneic Tumor Cells, in Rats with Bilateral Implanted N29 Tumors. ISRN Immunology, 2011, 2011, 1-13.	0.7	4
104	Tumor-tracking radiotherapy of moving targets; verification using 3D polymer gel, 2D ion-chamber array and biplanar diode array. Journal of Physics: Conference Series, 2010, 250, 012051.	0.3	6
105	The Interplay Effect in Gated and Non-gated IMRT for Breast Cancer: Impact of Breathing Motion and Gating Parameters. International Journal of Radiation Oncology Biology Physics, 2010, 78, S719.	0.4	0
106	Real-time dynamic MLC tracking for inversely optimized arc radiotherapy. Radiotherapy and Oncology, 2010, 94, 218-223.	0.3	62
107	Automated analysis of images acquired with electronic portal imaging device during delivery of quality assurance plans for inversely optimized arc therapy. Radiotherapy and Oncology, 2010, 94, 195-198.	0.3	15
108	Deviations in delineated GTV caused by artefacts in 4DCT. Radiotherapy and Oncology, 2010, 96, 61-66.	0.3	136

#	Article	IF	CITATIONS
109	A treatment planning study of the potential of geometrical tracking for intensity modulated proton therapy of lung cancer. Acta Oncológica, 2010, 49, 1141-1148.	0.8	11
110	Kilovoltage x-ray dosimetry—an experimental comparison between different dosimetry protocols. Physics in Medicine and Biology, 2008, 53, 4431-4442.	1.6	22
111	Experience from long-term monitoring of RAKR ratios in 192Ir brachytherapy. Radiotherapy and Oncology, 2008, 89, 217-221.	0.3	9
112	Survival of Rats with N29 Brain Tumours after Irradiation with 5 or 15 Gy and Immunization with IFN-gamma Secreting Tumour Cells. , 2008, , .		1
113	Modelling of an Orthovoltage X-ray Therapy Unit with the EGSnrc Monte Carlo Package. Journal of Physics: Conference Series, 2007, 74, 021009.	0.3	11
114	Monte Carlo calculations of thermal neutron capture in gadolinium: A comparison of GEANT4 and MCNP with measurements. Medical Physics, 2006, 33, 337-341.	1.6	29
115	Prompt gamma tomography during BNCT—a feasibility study. Journal of Instrumentation, 2006, 1, P05003-P05003.	0.5	11
116	An international dosimetry exchange for boron neutron capture therapy, Part I: Absorbed dose measurements. Medical Physics, 2005, 32, 3729-3736.	1.6	26
117	Gadolinium neutron capture brachytherapy (GdNCB), a new treatment method for intravascular brachytherapy. Medical Physics, 2005, 33, 46-51.	1.6	12
118	Quality assurance of patient dosimetry in boron neutron capture therapy. Acta Oncológica, 2004, 43, 404-411.	0.8	10
119	Boron Neutron Capture Therapy for Glioblastoma Multiforme: Clinical Studies in Sweden. Journal of Neuro-Oncology, 2003, 62, 135-144.	1.4	47
120	Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. Journal of Neuro-Oncology, 2003, 62, 135-144.	1.4	116
121	Reference dosimetry at the neutron capture therapy facility at Studsvik. Medical Physics, 2003, 30, 1569-1579.	1.6	13
122	Monte Carlo model of the Studsvik BNCT clinical beam: Description and validation. Medical Physics, 2003, 30, 3107-3117.	1.6	18
123	Toward clinical application of prompt gamma spectroscopy forin vivomonitoring of boron uptake in boron neutron capture therapy. Medical Physics, 2001, 28, 787-795.	1.6	30